Short Interest in Check-Cap Ltd (NASDAQ:MBAI) Declines By 63.5%

Check-Cap Ltd (NASDAQ:MBAIGet Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 65,685 shares, a decline of 63.5% from the May 14th total of 180,004 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average trading volume of 73,927 shares, the short-interest ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Check Out Our Latest Report on MBAI

Check-Cap Stock Performance

Shares of MBAI stock traded up $0.02 on Friday, hitting $1.39. The stock had a trading volume of 31,129 shares, compared to its average volume of 70,794. Check-Cap has a twelve month low of $0.59 and a twelve month high of $3.92. The firm has a market cap of $10.13 million, a price-to-earnings ratio of -0.50 and a beta of 0.59. The company has a fifty day simple moving average of $1.64.

About Check-Cap

(Get Free Report)

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.

Read More

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.